- Home
- TSSI vs MNPR Comparison
TSSI vs MNPR Comparison
Compare TSSI & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TSSI | MNPR |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.5M | 531.6M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | TSSI | MNPR |
|---|---|---|
| Price | $8.63 | $80.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $97.83 |
| AVG Volume (30 Days) | ★ 2.2M | 169.2K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.63 | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $234,837,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $45.78 | ★ N/A |
| Revenue Growth | ★ 91.66 | N/A |
| 52 Week Low | $5.63 | $20.16 |
| 52 Week High | $31.94 | $105.00 |
Technical Indicators
Market Signals| Indicator | TSSI | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 33.57 | 48.65 |
| Support Level | $8.60 | $74.00 |
| Resistance Level | $9.48 | $91.79 |
| Average True Range (ATR) | 0.74 | 7.21 |
| MACD | 0.20 | -0.89 |
| Stochastic Oscillator | 53.05 | 27.87 |
Price Performance
Historical ComparisonAbout TSSI TSS Inc.
TSS Inc provides various services for planning, design, development, and maintenance of mission-critical facilities and information infrastructure, as well as integration services. Its services consist of technology consulting, design and engineering, project management, systems integration, systems installation, facilities management, and IT procurement services. The activities are organized into two segments: Procurement, Systems Integration, and Facilities Management. It generates the majority of its revenue from the Procurement segment.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.